NVO:NYE-Novo Nordisk A/S (USD)

EQUITY | Drug Manufacturers - General | New York Stock Exchange

Last Closing

USD 67.35

Change

0.00 (0.00)%

Market Cap

USD 81.07B

Volume

6.50M

Analyst Target

USD 70.72
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes & obesity care and biopharmaceuticals.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-26 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
LLY Eli Lilly and Company

+11.51 (+1.61%)

USD 679.94B
JNJ Johnson & Johnson

+0.31 (+0.20%)

USD 364.11B
ABBV AbbVie Inc

+2.46 (+1.34%)

USD 323.71B
PFE Pfizer Inc

+0.29 (+1.24%)

USD 129.80B
BMY Bristol-Myers Squibb Company

+0.04 (+0.09%)

USD 95.34B
OGN Organon & Co

+0.45 (+5.18%)

USD 2.26B
GSK GlaxoSmithKline PLC ADR

+0.78 (+2.02%)

N/A
MRK Merck & Company Inc

+0.01 (+0.01%)

N/A
NVS Novartis AG ADR

+0.46 (+0.41%)

N/A

ETFs Containing NVO

OZEM Roundhill GLP-1 & Weight .. 16.41 % 0.00 %

+0.60 (+8.92%)

USD 0.03B
THNR Amplify ETF Trust 13.46 % 0.00 %

+0.45 (+8.92%)

USD 2.82M
RVER Advisor Managed Portfolio.. 6.55 % 0.00 %

+0.73 (+8.92%)

USD 0.08B
NVOX Defiance Daily Target 2X .. 6.41 % 0.00 %

+0.56 (+8.92%)

N/A
TTTX:CA Global X Innovative Bluec.. 6.29 % 0.00 %

+0.03 (+8.92%)

CAD 4.59M
LIFE-B:CA Evolve Global Healthcare .. 5.27 % 0.00 %

+0.29 (+8.92%)

N/A
QLTI The 2023 ETF Series Trust.. 4.30 % 0.00 %

+0.34 (+8.92%)

USD 0.04B
GINX SGI Enhanced Global Incom.. 3.16 % 0.00 %

+0.20 (+8.92%)

N/A
AVSD American Century ETF Trus.. 0.64 % 0.00 %

+0.93 (+8.92%)

USD 0.18B
HFXI IQ 50 Percent Hedged FTSE.. 0.00 % 0.20 %

+0.54 (+8.92%)

USD 1.03B
JPIN JPMorgan Diversified Retu.. 0.00 % 0.40 %

+0.44 (+8.92%)

N/A
RFAP 0.00 % 0.83 %

N/A

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

+0.10 (+8.92%)

CAD 0.05B
PTIN Pacer Trendpilot Internat.. 0.00 % 0.00 %

+0.33 (+8.92%)

USD 0.15B
PDEV 0.00 % 0.00 %

N/A

N/A
SLIM 0.00 % 0.50 %

N/A

N/A
TLTD FlexShares Morningstar De.. 0.00 % 0.39 %

+1.16 (+8.92%)

USD 0.50B
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.69 %

+0.11 (+8.92%)

CAD 0.22B
DMRI 0.00 % 0.50 %

N/A

N/A
IMEA:LSE 0.00 % 0.00 %

N/A

N/A
AVDE Avantis® International E.. 0.00 % 0.00 %

+0.99 (+8.92%)

USD 6.61B
BKIE BNY Mellon International .. 0.00 % 0.00 %

+1.15 (+8.92%)

USD 0.63B
LEAD-B:CA Evolve Future Leadership .. 0.00 % 0.00 %

+0.22 (+8.92%)

CAD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.70% 30% F 10% F
Dividend Return 1.28% 40% F 48% F
Total Return -20.43% 30% F 11% F
Trailing 12 Months  
Capital Gain -50.49% 20% F 4% F
Dividend Return 1.19% 20% F 25% F
Total Return -49.31% 20% F 4% F
Trailing 5 Years  
Capital Gain 114.52% 89% A- 83% B
Dividend Return 17.20% 33% F 48% F
Total Return 131.73% 78% C+ 82% B
Average Annual (5 Year Horizon)  
Capital Gain 31.46% 90% A- 91% A-
Dividend Return 32.98% 90% A- 91% A-
Total Return 1.52% 20% F 37% F
Risk Return Profile  
Volatility (Standard Deviation) 41.44% 10% F 19% F
Risk Adjusted Return 79.58% 80% B- 87% B+
Market Capitalization 81.07B 57% F 100% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - General) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 14.90 43% 46%
Price/Book Ratio 13.78 43% 6%
Price / Cash Flow Ratio 2.35 100% 71%
Price/Free Cash Flow Ratio 13.46 43% 34%
Management Effectiveness  
Return on Equity 88.12% 71% 99%
Return on Invested Capital 55.61% 100% 97%
Return on Assets 23.29% 100% 100%
Debt to Equity Ratio 58.71% 86% 55%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.